Back to discover
Disease
Pneumococcal Infections
Late-stage therapeutic developmentEmerging researchRising momentum
4
Publications
15
Clinical trials
1
Related treatments
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2024-09-27Nature communications
Research2024-02-01The Lancet. Infectious diseases
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents
- Q1 2027A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
- Q4 2028Immunogenicity and Safety of the 20-Valent Pneumococcal Conjugate Vaccine (PCV-20) Administered During an Acute Febrile Illness in Adults: a Multicentric Randomized Non-inferiority Trial
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20282026-03-30
Upcoming trial readoutHigh impact
Results expected Q1 20272026-02-27
Clinical MilestonesViewHide
Results expected
- 2026-03-30Immunogenicity and Safety of the 20-Valent Pneumococcal Conjugate Vaccine (PCV-20) Administered During an Acute Febrile Illness in Adults: a Multicentric Randomized Non-inferiority TrialResults expected Q4 2028
- 2026-02-27A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Results expected Q1 2027
- 2025-10-06A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and AdolescentsResults expected Q4 2026
Activity timeline3
- 2026-03-30ClinicalImmunogenicity and Safety of the 20-Valent Pneumococcal Conjugate Vaccine (PCV-20) Administered During an Acute Febrile Illness in Adults: a Multicentric Randomized Non-inferiority TrialResults expected Q4 2028
- 2026-02-27ClinicalA Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Results expected Q1 2027
- 2025-10-06ClinicalA Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and AdolescentsResults expected Q4 2026
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Clinical programme
15
6
12
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20132024
Most influential
Recent publications
Major themes6
- Pneumococcal Infections2
- Pneumococcal Vaccines2
- Streptococcus pneumoniae2
- Immunization Schedule1
- Population Surveillance1
- Vaccines, Conjugate1
Leading journals4
- Nature communications1
- PLoS medicine1
- Scientific reports1
- The Lancet. Infectious diseases1
Leading researchers8
- Abdullahi F1
- Anderson RM1
- Andrews NJ1
- Bentley SD1
- Bertran M1
- Cherian T1
- Chochua S1
- Cohen C1
Affiliations (unnormalised)6
- School of Public Health2
- Centers for Disease Control and Prevention1
- Centre for Respiratory Diseases and Meningitis1
- Johns Hopkins Bloomberg School of Public Health1
- London School of Hygiene & Tropical Medicine1
- Milner Centre for Evolution1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.